[1]郭 雪,石学军.替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析[J].医学信息,2020,33(07):71-75.[doi:10.3969/j.issn.1006-1959.2020.07.021]
　GUO Xue,SHI Xue-jun.Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer[J].Medical Information,2020,33(07):71-75.[doi:10.3969/j.issn.1006-1959.2020.07.021]
点击复制

替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
71-75
栏目:
论著
出版日期:
2020-04-01

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer
文章编号:
1006-1959（2020）07-0071-05
作者:
郭 雪; 石学军
（重庆医科大学附属永川医院肿瘤科，重庆 402160）
Author(s):
GUO Xue; SHI Xue-jun
(Department of Oncology,Yongchuan Hospital,Chongqing Medical University,Chongqing 402160,China)
关键词:
替吉奥; 卡培他滨; 放疗; 结直肠癌; Meta 分析
Keywords:
Tegafur; Capecitabine; Radiotherapy; Colorectal cancer; Meta analysis
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2020.07.021
文献标志码:
A
摘要:
目的 对替吉奥与卡培他滨同步放疗在复发性结直肠癌的疗效及安全性进行Meta分析。方法 2017年9月~2019年12月计算机检索PubMed、The Cochrane Library、Embase、VIP、CKNI、万方数据库，按照纳入和排除标准筛选文献和提取资料后，采用RevMan 5.3 软件进行Meta分析。结果 最终纳入8篇文献，包括706例患者。Meta分析结果显示，替吉奥同步放疗较卡培他滨能有效改善复发性结直肠癌的客观缓解率，差异有统计学意义[OR=2.23,95%CI（1.59，3.13）]，P＜0.00001]；替吉奥同步放疗较卡培他滨能有效改善复发性结直肠癌的疾病控制率，差异有统计学意义[OR=3.63,95%CI（2.00，6.57），P＜0.0001]；第1、第2、第3年生存率比较，差异有统计学意义[OR=3.48,95%CI（1.98，6.13），P＜0.0001]、[OR=2.35,95%CI（1.55，3.55），P＜0.0001]、[OR=1.94,95%CI（1.30，2.90），P=0.001]。替吉奥同步放疗手足综合征发生率低于卡培他滨同步放疗，差异有统计学意义[OR=0.33,95%CI（0.13，0.81），P=0.02]；恶心、呕吐等消化道反应[OR= 0.74,95%CI（0.5，1.10），P=0.14]、放射性直肠炎[OR=0.72,95%CI（0.42，1.24），P=0.24]与对照组比较，差异无统计学意义。结论 在治疗复发性结直肠癌方面，替吉奥同步放疗与卡培他滨同步放疗比较，前者能有效改善客观缓解率，在手足综合征方面具有更良好的安全性。
Abstract:
Objective To conduct a meta-analysis on the efficacy and safety of simultaneous radiotherapy of Tegafur and capecitabine in recurrent colorectal cancer.Methods The computer searched PubMed, The Cochrane Library, Embase, VIP, CKNI, Wanfang databases, after screening literature and extracting data according to the inclusion and exclusion criteria, using RevMan 5.3 software for Meta analysis from September 2017 to December 2019.Results 8 articles were finally included, including 706 patients. Meta analysis results showed that Tegafur simultaneous radiotherapy can effectively improve the objective remission rate of recurrent colorectal cancer compared with capecitabine, the difference was statistically significant [OR=2.23,95%CI (1.59, 3.13)],P<0.00001];Tegafur simultaneous radiotherapy can effectively improve the disease control rate of recurrent colorectal cancer compared with capecitabine, the difference was statistically significant[OR=3.63,95%CI (2.00,6.57),P<0.0001];Comparison of survival rates in the first, second, and third years respectively, the difference was statistically significant [OR=3.48,95%CI (1.98,6.13),P<0.0001], [OR=2.35,95%CI (1.55,3.55),P<0.0001],[OR =1.94,95%CI(1.30,2.90),P=0.001].The incidence of hand-foot syndrome was lower than capecitabine in simultaneous radiotherapy for Tegafur,the difference was statistically significant[OR=0.33,95%CI (0.13, 0.81),P=0.02]; nausea, vomiting and other gastrointestinal reactions [OR=0.74,95%CI (0.5,1.10),P=0.14], radiation proctitis[OR=0.72,95%CI(0.42,1.24),P=0.24] compared with the control group, the difference was not statistically significant.Conclusion In the treatment of recurrent colorectal cancer, compared with synchronous radiotherapy of Tegafur and capecitabine, the former can effectively improve the objective remission rate and has better safety in hand-foot syndrome.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA,2018,68(6):394-424.[2]郑荣寿,孙可欣,张思维,等.2015中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.[3]陈万青,郑荣寿,张思维,等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2016,25(1):1-8.[4]Moriya Y.Treatment strategy for locally recurrent rectal cancer[J].Jpn J Clin Oncol,2006(36):127-131.[5]Nielsen MB,Laurberg S,Holm T.Current management of locally recurrent rectal cancer[J].Colorectal Dis,2011(13):732-742. [6]Caceres M,Pascual M,Alonso S,et al.Treatment of colorectal cancer with unresectable metastasis with chemotherapy without primary tumor resection:analysis of tumor-related complications[J].Cir Esp,2014,92(1):30-37.[7]Nakagawa R,Inoue Y,Ohki T,et al.Erratum to: Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients:a single center experience retrospective analysis[J].World J Surg Oncol,2017,15(1):171. [8]胡方宽,王亚楠,邓业巍,等.替吉奥或卡培他滨同步三维适形放疗治疗中老年复发直肠癌疗效[J].世界华人消化杂志,2014,22(3):439-443.[9]臧晔.替吉奥化疗同步三维适形放疗治疗复发性结直肠癌的疗效与安全性研究[J].吉林医学,2018,39(5):906-907.[10]王新宁,赖德星,杜月群,等.调强放疗同步替吉奥化疗治疗局部晚期或复发性直肠癌的临床研究[J].临床医学工程,2019, 26(3):320-322.[11]顾立强.替吉奥化疗联合三维适形放疗治疗复发性结直肠癌的疗效分析[J].吉林医学,2015,36(5):840.[12]周勇,杨勇.两种同步放化疗方案对复发性结直肠癌患者生存时间及不良反应的影响[J].检验医学与临床,2017(1411):1565-1567.[13]陈静.替吉奥或卡培他滨同步三维适形放疗治疗中老年复发直肠癌的临床疗效分析[J].现代诊断与治疗,2017,28(7):1221-1222.[14]王刚,郝勤玲,刘旭,等.替吉奥或卡培他滨同步三维适形放疗治疗中老年复发直肠癌的临床疗效[J].中国老年学杂志,2015,35(2):344-346.[15]马杰,姚林果,刘世君,等.替吉奥与卡培他滨同步放疗用于结肠癌根治术后复发患者的效果比较[J].中国药房,2017,28(26):3691-3693.[16]Andre T,Gramont AD,Vernerey D,et al.Adjuvant Fluorouracil,Leucovorin,and Oxaliplatin in Stage II to III ColonCancer:Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study[J].J Clin Oncol,2015,33(35):4176-4187.[17]But-Hadzic J,Anderluh F,Brecelj E,et al.Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost:A Phase 2 Trial[J].Int J Radiat Oncol Biol Phys,2016,96(5):1003-1010. [18]Sun Z,Adam MA,Kim J,et al.Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer[J].J Gastrointest Surg,2017,21(1):106-111. [19]Zhu XG,Li YH,Li XF,et al.Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: longterm results from a single institution[J].Am J Transl Res,2016,8(2): 1265-1272.[20]Tanaka H.Effect of capecitabine therapy on the blood levels of antiepi leptic drugs:report of two cases[J].Gan To Kagaku Ryoho,2014,41(4):527-530.[21]Nakagawa R,Inoue Y,Ohki T,et al.Efficacy and shortterm outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis[J].World J Surg Oncol,2017,15(1):112. [22]Sadahiro S,Suzuki T,Tanaka A,et al.Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer[J].Cancer Chemother Pharmacol,2017,79(6):1077-1085.[23]Tahara M,Kiyota N,Mizusawa J,et al.Phase Ⅱ trial ofchemoradiotherapy with S-1 plus cisplatin for unresectable locallyadvanced head and neck cancer(JCOG0706)[J].Cancer Sci,2015,106(6):726-733.[24]Yamazaki K, Kuwano H, Ojima H,et al.A randomized phase Ⅱstudy of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer[J].Cancer Chemotherapy and Pharmacology,2015,75(3):569-577.[25]穆毅,谭昊,王茜,等.替吉奥联合调强放疗治疗复发性直肠癌的疗效分析[J].肿瘤药学,2018,8(6):927-930.

相似文献/References:

[1]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(07):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[2]李 光.替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析[J].医学信息,2018,31(16):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
　LI Guang.Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer[J].Medical Information,2018,31(07):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
[3]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Medical Information,2018,31(07):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[4]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(07):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[5]王逸飞,王 志,左宏波,等.伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究[J].医学信息,2019,32(07):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
　WANG Yi-fei,WANG Zhi,ZUO Hong-bo,et al.Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer[J].Medical Information,2019,32(07):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
[6]林飞帆,石学军,王春光.替吉奥对比卡培他滨在晚期乳腺癌疗效及安全性的Meta分析[J].医学信息,2019,32(10):91.[doi:10.3969/j.issn.1006-1959.2019.10.029]
　LIN Fei-fan,SHI Xue-jun,WANG Chun-guang.Meta-analysis of the Efficacy and Safety of Tiggio Versus Capecitabine in Advanced Breast Cancer[J].Medical Information,2019,32(07):91.[doi:10.3969/j.issn.1006-1959.2019.10.029]
[7]那文秀.奥沙利铂联合卡培他滨治疗晚期胃癌的疗效[J].医学信息,2020,33(06):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]
　NA Wen-xiu.Efficacy of Oxaliplatin Combined with Capecitabine in the Treatment of Advanced Gastric Cancer[J].Medical Information,2020,33(07):144.[doi:10.3969/j.issn.1006-1959.2020.06.046]
[8]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Medical Information,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
[9]谢兴江,彭 强,侯松林,等.SOX和XELOX在进展期胃癌新辅助化疗中疗效及不良反应差异的Meta分析[J].医学信息,2021,34(07):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]
　XIE Xing-jiang,PENG Qiang,HOU Song-lin,et al.Meta-analysis of the Differences in the Efficacy and Adverse Reactions of SOX and XELOX in Neoadjuvant Chemotherapy for Advanced Gastric Cancer[J].Medical Information,2021,34(07):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]

更新日期/Last Update: 2020-04-01